Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

641 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Pharmacokinetic and pharmacodynamic study of ipragliflozin in Japanese patients with type 2 diabetes mellitus: a randomized, double-blind, placebo-controlled study.
Kadokura T, Akiyama N, Kashiwagi A, Utsuno A, Kazuta K, Yoshida S, Nagase I, Smulders R, Kageyama S. Kadokura T, et al. Among authors: kashiwagi a. Diabetes Res Clin Pract. 2014 Oct;106(1):50-6. doi: 10.1016/j.diabres.2014.07.020. Epub 2014 Jul 26. Diabetes Res Clin Pract. 2014. PMID: 25149596 Clinical Trial.
Effects of ipragliflozin, a selective sodium-glucose co-transporter 2 inhibitor, on blood pressure in Japanese patients with type 2 diabetes mellitus: a pooled analysis of six randomized, placebo-controlled clinical trials.
Kashiwagi A, Yoshida S, Kawamuki K, Nakamura I, Kazuta K, Ueyama E, Takahashi H, Akiyama N, Kondo Y, Ogihara T. Kashiwagi A, et al. Diabetol Int. 2016 Sep 9;8(1):76-86. doi: 10.1007/s13340-016-0283-x. eCollection 2017 Mar. Diabetol Int. 2016. PMID: 30603310 Free PMC article.
A Prospective, Open-Label Short-Term Pilot Study on Modification of the Skin Hydration Status During Treatment With a Sodium-Glucose Cotransporter-2 Inhibitor.
Tezuka Y, Sekine O, Hirano A, Hanada Y, Nakanishi I, Ariga M, Azuma C, Yamamoto Y, Ito-Kobayashi J, Washiyama M, Iwanishi M, Furuta M, Kanamori M, Shimatsu A, Kashiwagi A. Tezuka Y, et al. Among authors: kashiwagi a. Diabetes Ther. 2021 Jan;12(1):431-440. doi: 10.1007/s13300-020-00950-7. Epub 2020 Oct 27. Diabetes Ther. 2021. PMID: 33108650 Free PMC article.
Reduction in cardiovascular disease events in patients with type 2 diabetes mellitus treated with a sodium-glucose cotransporter 2 inhibitor versus a dipeptidyl peptidase-4 inhibitor: A real-world retrospective administrative database analysis in Japan.
Kashiwagi A, Shoji S, Onozawa S, Kosakai Y, Waratani M, Ito Y. Kashiwagi A, et al. J Diabetes Investig. 2022 Jul;13(7):1175-1189. doi: 10.1111/jdi.13785. Epub 2022 Apr 9. J Diabetes Investig. 2022. PMID: 35243799 Free PMC article.
641 results